MAPK3 and plasma cell myeloma: Previously, in a bortezomib- and lenalidomide-refractory myeloma patient, we have shown that constitutive activation of RAS signalling, as evidenced by over-expression of phospho-ERK1/2 by Western blot, was attributed by BRAF V600E but not KRAS/NRAS mutation11.